Climb Bio has stabilized its post-acquisition burn rate, with quarterly net losses narrowing from $54.9M in 2024Q2 to $13.5M in 2026Q2, reflecting disciplined R&D and SG&A spending. The company's strategic pivot to budoprutug for autoimmune diseases positions ...
Price trend, volume and key moving averages
Trailing total returns as of 9/9/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | -$0.18+14.0% vs -$0.21 | — vs — |
Q2 2026 May 7, 2026 | -$0.20+23.1% vs -$0.26 | — vs — |
Q2 2026 Mar 5, 2026 | -$0.26-30.0% vs -$0.20 | — vs — |
Q4 2025 Nov 6, 2025 | -$0.19-18.8% vs -$0.16 | — vs — |
WELLESLEY HILLS, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that members of its executive team will participate in the upcoming conferences detailed below.
Climb Bio, Inc. (NASDAQ: CLYM - Get Free Report) shot up 10.9% on Monday after Wedbush raised their price target on the stock from $17.00 to $20.00. Wedbush currently has an outperform rating on the stock. Climb Bio traded as high as $14.25 and last traded at $14.24. Approximately 228,260 shares changed hands during trading, a
Climb Bio, Inc. (NASDAQ: CLYM - Get Free Report)'s stock price reached a new 52-week high during trading on Tuesday after Wedbush raised their price target on the stock from $17.00 to $20.00. Wedbush currently has an outperform rating on the stock. Climb Bio traded as high as $14.42 and last traded at $12.79, with a
Climb Bio: Three Key Kidney Disease Readouts In Q4 Ought To Generate Volatility
Benchmark CLYM against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Climb Bio, Inc. (CLYM)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $15.90 | $910.48M | -18.07 | — | — | -32.15% | — | |
| $39.57 | $8.17B | -14.29 | — | -7585.86% | -69.59% | — | |
| $24.39 | $3.05B | -187.62 | 91.34% | 6.15% | 15.05% | — | |
| $21.53 | $2.22B | -20.70 | 20.6% | -67.85% | -23.43% | — | |
| $116.47 | $9.58B | -31.56 | -16.72% | -285.41% | -21.5% | — | |
| $352.48 | $9.83B | -26.15 | -100% | — | -34.15% | — |
Climb Bio, Inc. (CLYM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when CLYM posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Climb Bio, Inc. (CLYM) stock FAQ — growth, dividends, profitability & financials explained
Climb Bio, Inc. (CLYM) reported a net loss of $57.6M for fiscal year 2025.
Climb Bio, Inc. (CLYM) has a return on equity (ROE) of -32.1%. Negative ROE indicates the company is unprofitable.
Climb Bio, Inc. (CLYM) had negative free cash flow of $53.1M in fiscal year 2025, likely due to heavy capital investments.
